22 citations,
May 2011 in “European Journal of Cancer” In this Phase I study, 25 patients with advanced solid tumors were treated with SU-014813 and docetaxel to determine the maximal tolerated dose, evaluate pharmacokinetics, and assess anti-tumor efficacy. The recommended phase II dose was 75 mg/m² of docetaxel with 50 mg/day of SU-014813. Dose-limiting toxicities included neutropenia, neutropenic fever, fatigue, and diarrhea. Common side effects were fatigue, alopecia, nausea, vomiting, anorexia, rash, hypertension, and hair discoloration. The clinical benefit rate was 37.5%, with 2 patients achieving partial responses and 7 patients having stable disease for over 6 months. The combination showed manageable safety and promising anti-tumor activity, particularly in melanoma and sunitinib-refractory gastrointestinal stromal tumors, warranting further development.
3 citations,
August 2020 in “Cutaneous and Ocular Toxicology” ATP helps prevent skin damage from vandetanib by reducing stress.
53 citations,
April 2018 in “Journal of The American Academy of Dermatology” Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.
February 2018 in “Journal of the advanced practitioner in oncology” Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.
54 citations,
September 2012 in “Acta ophthalmologica” Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.